Acute Promyelocytic Leukemia
Conditions
Keywords
APL, acute promyelocytic leukemia (M3), high-risk acute promyelocytic leukemia (APL/AML M3), acute myeloid leukemia with t(15;17)(q22;q12), newly diagnosed, high-risk
Brief summary
Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) characterized by consistent clinical, morphologic, and genetic features. According to the FAB classification APL is designated as"M3 leukemia" and assigned to the WHO defined type of AML with recurrent cytogenetic abnormalities, "acute promyelocytic leukemia with t(15;17)(q22;q12), (PML/RARα) and variants". Despite the dramatic progress achieved in frontline therapy of APL with ATRA plus anthracycline-based regimens, relapses still occur in approximately 20% of patients. Moreover, these regimens are associated with significant toxicities due to severe myelosuppression frequently associated with life-threatening infections and potentially serious late effects including development of secondary MDS/AML. In a recent randomized clinical trial in low/intermediate-risk APL (WBC ≤ 10 GPt/l APL0406 trial) a combination of arsenic trioxide (ATO) and ATRA has been shown to result into better survival with significantly lower toxicity rates compared to the standard ATRA + idarubicin (AIDA) therapy. Inspired by the results of this trial the investigators intend to perform a randomized study in high-risk APL (WBC at diagnosis \> 10 GPt/l) comparing standard AIDA-based treatment with ATO/ATRA combination including low-doses idarubicin during induction. The investigators propose a modified ATO/ATRA protocol with the addition of two doses of IDA (50% compared to standard AIDA induction) for induction because of the anticipated need of adding anthracyclines to control hyperleukocytosis and to achieve long-term disease control in this high-risk APL population. This is followed by 4 cycles of ATO/ATRA consolidation therapy. As in the APL0406 study for low/intermediate-risk patients the investigators expect less severe hematologic toxicity and treatment-related mortality resulting in an improved outcome for patients in the experimental arm. Furthermore, from the start of consolidation, these patients (in contrast to the standard arm) can be treated on an outpatient basis, which is also considered to be associated with an improved quality of life. The study will be conducted as a European intergroup study.
Interventions
DRUGArsenic trioxide
DRUGIdarubicin
DRUGCytarabine
DRUGTretinoin
DRUGMitoxantrone
DRUGMercaptopurine
DRUGMethotrexate
Sponsors
Technische Universität Dresden
Gruppo Italiano Malattie EMatologiche dell'Adulto
Groupe Francophone des Myelodysplasies
HOVON - Dutch Haemato-Oncology Association
Programa para el Tratamiento de Hemopatías Malignas
German Federal Ministry of Education and Research
Teva Pharmaceuticals Europe
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Informed consent * Women or men with a newly diagnosed APL by cytomorphology, confirmed by molecular analysis\* * Age ≥ 18 and ≤ 65 years * ECOG performance status 0-3 * WBC at diagnosis \> 10 GPt/l * Serum total bilirubin ≤ 3.0 mg/dl (≤ 51 µmol/l) * Serum creatinine ≤ 3.0 mg/dl (≤ 260 µmol/l) * Women must fulfill at least one of the following criteria in order to be eligible for trial inclusion: * Post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with Serum FSH \> 40 U/ml) * Postoperative (i.e. 6 weeks) after bilateral ovariectomy with or without hysterectomy * Continuous and correct application of a contraception method with a Pearl Index of \<1% (e.g. implants, depots, oral contraceptives, -intrauterine device - IUD) * Sexual abstinence * Vasectomy of the sexual partner * The confirmation of diagnosis at genetic level (microspeckled PML nuclear distribution by PGM3 monoclonal antibody and/or PML/RARa fusion by RT-PCR or fluorescence in situ hybridization (FISH) and/or demonstration of t(15;17) at karyotyping) will be mandatory for patient eligibility. However, in order to avoid delay in treatment initiation, patients can be randomized on the basis of morphologic diagnosis only and before the results of genetic tests are available
Exclusion criteria
* Patients who are not eligible for chemotherapy as per discretion of the treating physician * APL secondary to previous radio- or chemotherapy for non-APL disease * Other active malignancy at time of study entry (exception: basal-cell carcinoma) * Lack of diagnostic confirmation at genetic level * Significant arrhythmias, ECG abnormalities: * Congenital long QT syndrome; * History or presence of significant ventricular or atrial tachyarrhythmia; * Clinically significant resting bradycardia (\<50 beats per minute) * QTc \>500msec on screening ECG for both genders (using the QTcF formula detailed on protocol) * Right bundle branch block plus left anterior hemiblock, bifascicular block * Other cardiac contraindications for intensive chemotherapy (L-VEF \<50%) * Uncontrolled, life-threatening infections * Severe non controlled pulmonary or cardiac disease * Severe hepatic or renal dysfunction * HIV and/or active hepatitis C infection * Pregnant or breast-feeding patients * Allergy to trial medication or excipients in study medication * Substance abuse; medical, psychological or social conditions that may interfere with the patients participation in the study or evaluation of the study results * Use of other investigational drugs at the time of enrolment or within 30 days before study entry
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Event-free survival | From date of randomization until the date of first documented event, assessed up to 66 months | events are: no achievement of haematological complete remission after induction therapy; no achievement of molecular remission after the last consolidation course; relapse; death including early death or development of secondary AML or MDS |
Secondary
| Measure | Time frame |
|---|---|
| Rate of hematological complete remission | up to 60 days, from date of randomization until end of induction therapy |
| Rate of early death within 30 days after randomization | up to 30 days after randomization |
| Rate of overall survival (OS) | at 2 years |
| Rate of cumulative incidence of secondary MDS or AML | assessed up to 66 months, from date of randomization until occurance of secondary AML or MDS |
| Rate of cumulative incidence of relapse (CIR) | at 2 years |
| Incidence of hematological and non-hematological toxicity | assessed up to 30 months after randomization |
| Rate of molecular remission after the last consolidation cycle | up to 256 days after randomization |
| Assessment of acute promyelocytic leukemia/RARa transcript level reduction after induction therapy until end of study | assessed up to 30 months after randomization |
| Quality of Life at the end of induction therapy until the end of study | assessed up to 30 months after randomization |
| To investigate differences in the immune reconstitution between the two arms | assessed up to 30 months after randomization |
| Total hospitalization days during therapy | assessed up to 30 months after randomization |
Countries
France, Germany, Italy, Netherlands, Spain
Contacts
PRINCIPAL_INVESTIGATORUwe Platzbecker, Prof. Dr.
Technische Universität Dresden (TUD)
Outcome results
None listed